Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab in Neoadjuvant Cutaneous Squamous Cell Carcinoma
NCT04808999Phase 2Active, not recruiting
- Start
- May 2021
- Primary completion
- Apr 2024
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2 trial of pembrolizumab. Started May 2021; status: active, not recruiting.
02
Drugs
Beyond the preview
Go deeper on NCT04808999.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04808999.